Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498950 | 0.80 | PDK1 (0.41) | SMN1; SMN2GPR119USP30 | |
| SCHEMBL3497370 | 0.75 | USP30 (0.45) | DDB1CRBNEPHX2USP2SMN1; SMN2 | |
| SCHEMBL3497906 | 0.74 | USP2 (0.39) | DDB1CRBNEPHX2F2RL1USP2 | |
| SCHEMBL3498100 | 0.73 | USP30 (0.39) | DDB1CRBNEPHX2GRIN2BGRIN2C | |
| SCHEMBL3497376 | 0.73 | USP2 (0.41) | DDB1CRBNEPHX2USP2SMN1; SMN2 | |
| SCHEMBL12502141 | 0.65 | CHRM2 (0.35) | DDB1CRBNEPHX2GRIN2BGRIN2C | |
| SCHEMBL12502143 | 0.65 | CHRM2 (0.35) | DDB1CRBNEPHX2GRIN2BGRIN2C | |
| SCHEMBL693172 | 0.64 | USP2 (0.55) | EPHX2USP2SMN1; SMN2GPR119 | |
| SCHEMBL26426348 | 0.64 | GRIN2B (0.42) | DDB1CRBNEPHX2GRIN2BGRIN2C | |
| SCHEMBL14221991 | 0.64 | USP30 (0.39) | DDB1CRBNGRIN2BGRIN2CUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | DDB1 3880/4885CRBN 3367/4885EPHX2 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.